Page 10 - Biomedicine

Potential Investment and

Collaboration Opportunities

in Taiwan

Entering the biotechnology and
1
pharmaceutical industry clusters in Taiwan

In addition to its complete industrial development hubs in the biopharmacy
eld, Taiwan also has abundant data accumulated from the National Health Insurance
system, clinical experiences, and R&D capabilities, which will help international
biotech enterprises set up R&D centers or production sites in Taiwan. The government
has identified the biopharmaceutical industry as one of its core strategic industries,
and has launched the Biomedical Industry Innovation Promotion Project in order to
"build a complete industrial ecosystem," "integrate innovative clusters," "make use of
resources on the international market," and "promote characteristic and key industries,"
thereby supporting the manufacture of reagents and the research and development
of new drugs and vaccines. The impact of the current COVID-19 pandemic has fully
demonstrated the advantages and capabilities of Taiwan in the biopharmaceutical
and biotechnology industries. Foreign companies will be able to jointly take part in
the development of the biopharmaceutical industry in Taiwan through collaboration
among industry, the government, academia, and the research community in research
and development, technical transfer, among other undertakings.

Seizing business opportunities in the
2
biotechnology and pharmaceutical industries

Taiwan has competitive advantages in the biotechnology, pharmaceutical,
and medical device elds. Taiwan's regulatory requirements governing the approval
process for medicinal products are on a par with their international counterparts.
In addition, Taiwan has robust R&D capabilities and biomedical talent, as well as
abundant international clinical trial experience. It is home to more than 20 medical

08